参麦注射液治疗晚期非小细胞肺癌化疗患者癌因性疲乏:随机对照试验研究方案
本研究为两组前瞻性随机对照试验,评估在常规治疗基础上加用参麦注射液(SMI)治疗晚期非小细胞肺癌(NSCLC)化疗患者癌因性疲乏(CRF)的疗效与安全性。合格参与者随机接受5天SMI方案加常规治疗或仅常规治疗,主要结局为FACIT-F疲乏严重程度评分。研究旨在为全国范围内CRF管理提供可推广的临床决策证据。
要点
- 参麦注射液联合常规治疗用于晚期NSCLC化疗患者癌因性疲乏。
- 主要结局为FACIT-F疲乏严重程度评分,第5天干预结束时评估。
核心结论
- 本试验旨在评估参麦注射液加常规治疗对晚期NSCLC化疗患者癌因性疲乏的疗效与安全性。
研究设计与样本
- 研究为两组、前瞻性、随机对照试验(RCT)。
- 合格参与者随机分为治疗组(5天参麦注射液方案加常规治疗)或对照组(仅常规治疗)。
- 主要结局为采用FACIT-F测量系统严重程度评分评估的疲乏。
- 次要结局包括症状困扰评分、抑郁、睡眠障碍、生活质量及免疫指标水平。
- 评估在基线和第5天(干预结束)进行。
关键数值与推荐
- 治疗组接受5天参麦注射液方案加常规治疗,对照组仅接受常规治疗。
- 主要结局为FACIT-F疲乏严重程度评分。
- 次要结局包括症状困扰评分、抑郁、睡眠障碍、生活质量及免疫指标水平。
- 评估时间点为基线和第5天(干预结束)。
临床怎么用
- 本研究可为NSCLC化疗患者CRF管理的临床决策提供证据支持,并可在全国范围内推广使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer-related fatigue (CRF) is the most common symptom in patients with advanced non-small cell lung cancer (NSCLC) undergoing treatment with chemotherapy. However, evidence upon which to base management strategies is scarce. Traditional Chinese Medicine (TCM) has been shown to be beneficial to patients with CRF. Chinese herbal injections should be administered under an evidence-based approach. This trial aims to assess the efficacy and safety of the addition of the Shenmai injection (SMI) to conventional therapy for CRF in NSCLC patients undergoing chemotherapy. METHODS/DESIGN: The study is a two-group, prospective, randomized controlled trial (RCT) designed to evaluate the efficacy and safety of SMI for CRF NSCLC patients undergoing chemotherapy. Eligible participants will be randomized to either a treatment group receiving a 5-day Shenmai injection regimen plus conventional therapy or a control group receiving only conventional therapy. The primary outcome is fatigue, assessed using severity scores from the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F) measurement system. Secondary outcomes include symptom distress scores, depression, sleep disorders, quality of life, and levels of immunologic indicators. Assessments will be carried out at baseline and on day 5 (the end of the intervention). DISCUSSION: This study can provide evidence to support clinical decision-making in the management of CRF in NSCLC patients undergoing chemotherapy in a way that can be scaled up and used throughout China. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( chictr.org.cn ), ChiCTR-INR-17013737 . Registered on 6 December 2017.
引用
- Zhou Y, Zhao B, Wu W, et al. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30180874. doi:10.1186/s13063-018-2845-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。